Natco Pharma Q3 net profit declines 34% to Rs 104 crore
Consolidated total income stood at Rs 513 crore for the quarter under consideration.

Consolidated total income stood at Rs 513 crore for the quarter under consideration. It was Rs 580 crore for the same period a year ago.
"The company continues to face margin pressures in its Hepatitis C portfolio," the filing said.
The company's board has recommended a third interim dividend of Rs 3.50 per equity share of Rs 2 each.
Shares of Natco Pharma closed at Rs 712 per scrip on BSE, down 0.59 per cent from its previous close.
Download ET Markets APP